ROVI reports operating revenue growth of 53% and doubles its ebitda
- Operating revenue increased by 53% to 463.5 million euros driven by (i) the strength of the contract manufacturing organization (“CMO”) business, which grew by 187%, and (ii) the specialty pharmaceutical business, where sales rose 18%.
- Sales of the heparin franchise (Low Molecular Weight Heparins (LMWH) and other heparins) increased by 15% to 181.5 million euros. Sales of the enoxaparin biosimilar increased 17% to 89.9 million euros and sales of Bemiparin increased 13% to 86.3 million euros.
- EBITDA doubled to 139.5 million euros.
- Net profit increased by 111% to 98.9 million euros.
- ROVI’s ESG aspects have been evaluated by Sustainalytics, having obtained an “ESG Risk Rating 2021” of 18.4, which places the company at low risk (between 10 and 20). ROVI has attained the second position out of 432 companies in the sub-industry “pharmaceuticals”. ROVI General Shareholders Meeting approved the payment of a gross dividend of 0.3812 euros per share on 2020 earnings (+118%). This dividend was paid on July, 7th.